Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tongxin Medical Technology

Request full access

Designs and manufactures medical devices for use in the healthcare industry

ChinaFounded 2008Health Tech & Medtech

About Tongxin Medical Technology

CH Biomedical, operating in the U.S. as BrioHealth Solutions, Inc., is a medical technology company established in 2008 by Dr. Chen Chen. Dr. Chen has over two decades of experience in the field of ventricular assist devices (VADs), beginning with academic research into the application of magnetic levitation. His journey includes developing the World Heart Levacor VAD before he founded CH Biomedical to create a smaller, more effective artificial heart. The company focuses on developing and commercializing VADs for patients with severe heart failure.

The firm's primary product is a fully magnetically levitated left ventricular assist device (LVAD), known as an "artificial heart." Its first-generation product, the CH-VAD, was launched after seven years of development and is designed to serve as either a bridge-to-transplantation or as destination therapy for individuals with end-stage heart failure. This device, made of titanium alloy, functions as a centrifugal pump that assists a malfunctioning heart by pumping blood from the veins to the arteries. A key feature of the CH-VAD is its fully magnetically levitated flow technology, which suspends the rotor with magnetic forces, allowing for gentler passage of blood cells. The device is notably compact, weighing under 180g, with a thickness of 26mm and a diameter of 50mm, and connects to an external wearable battery via a minimal number of cords. Since its first human implantation in 2017, the CH-VAD received market approval in China in 2021 and has been utilized in over 180 patients across more than 40 hospitals in the country.

Building on the technology of the CH-VAD, the company has developed its next-generation product, the BrioVAD™ Left Ventricular Assist System. This system received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) in May 2024 to begin clinical trials. The BrioVAD aims to enhance portability and overall system performance through several technological innovations while maintaining the blood compatibility of its predecessor. The company, headquartered in Suzhou, China, with a U.S. subsidiary in Burlington, Massachusetts, operates on a business model centered on the development, manufacturing, and sale of these high-end medical devices to hospitals and cardiac centers. CH Biomedical has secured significant funding, including a Series D round of over $100 million, to accelerate its international expansion and continue its product innovation.

Source: Dealroom company data

At a glance

Status
Operational
Employees
18
Open positions
None listed
Dealroom signal
40.6/100
Industry
Health
Sub-industry
Medical Devices
Sector
Cardiology and cardiovascular, Rumoured $1B, DT and LS, science-based
Technology
Hardware, Deep Tech
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Jul 2025 $100M $400M HongShan · China Growth Capital · Gaorong Capital · Neovision Capital ↗
SERIES DOther financing Jan 2022 $28M $110M Jiantou Huawen Investment · PICC Capital · CICC · HongShan ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Tongxin Medical Technology website traffic

Latest recorded traffic for Tongxin Medical Technology is 80 monthly website visits, down 98.1% over the last three months. Tongxin Medical Technology's team declined 18.2% over the past year.

Latest monthly visits80 3-month web change-98.1% 1-year team growth-18.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Tongxin Medical Technology in its local ecosystem

Live from Dealroom

The Tongxin Medical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

13 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later13 investors entered at this stage

  • Linden Asset Group
  • Sequoia
  • Lake Bleu Capital
  • Jiantou Huawen Investment
  • PICC Capital
  • CICC
  • HongShan
  • Honghui China
  • Qingchi Capital
  • Lingdao Capital
  • China Growth Capital
  • Gaorong Capital
  • Neovision Capital
Employees 18 total headcount
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China87.5%
🇺🇸 United States12.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tongxin Medical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tongxin Medical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.